Search Results - "Castellano, M E"

Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic‐guided prophylaxis based on Bayesian models with myPKFiT by Mingot‐Castellano, M. E., Parra, R., Núñez, R., Martorell, M.

“…Objectives Patients with severe haemophilia A (HA) receive factor VIII (FVIII) replacement therapy as prophylaxis. myPKFiT®is an online medical application…”
Get full text

Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study by James, P. D., Mahlangu, J., Bidlingmaier, C., Mingot-Castellano, M. E., Chitlur, M., Fogarty, P. F., Cuker, A., Mancuso, M. E., Holme, P. A., Grabell, J., Satkunam, N., Hopman, W. M., Mathew, P.

“…Introduction There has been increasing recognition in recent years that female carriers of haemophilia manifest abnormal bleeding; however, data on the use of…”
Get full text

Moderate and severe haemophilia in Spain: An epidemiological update by Aznar, J. A., Altisent, C., Álvarez‐Román, M. T., Bonanad, S., Mingot‐Castellano, M. E., López, M. F.

Get full text

Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey by Fogarty, P. F., Mancuso, M. E., Kasthuri, R., Bidlingmaier, C., Chitlur, M., Gomez, K., Holme, P. A., James, P., Kruse-Jarres, R., Mahlangu, J., Mingot-Castellano, M. E., Soni, A.

“…Summary Sparse data are available on presentation and management of acute coronary syndromes (ACS), including unstable angina and non‐ST‐ and ST‐elevation…”
Get full text

Gender diversity and autism spectrum disorder in child and youth population by Rodríguez, P R, Grimal, M M, Castellano, E E M, Batista, F A R, Pérez, N M

“…IntroductionInterest in the co-occurrence of gender dysphoria and autism spectrum disorder has gained prominence in recent years. Gender dysphoria refers to…”
Get full text

Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain by Villarrubia, R., Oyagüez, I., Álvarez-Román, M. T., Mingot-Castellano, M. E., Parra, R., Casado, M. A.

“…Objective: A cost analysis model was developed to compare annual cost of prophylaxis with activated prothrombin complex concentrate (aPCC) vs. on‐demand…”
Get full text

Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series by Iorio, A., Barbara, A. M., Makris, M., Fischer, K., Castaman, G., Catarino, C., Gilman, E., Kavakli, K., Lambert, T., Lassila, R., Lissitchkov, T., Mauser‐Bunschoten, E., Mingot‐Castellano, M. E., Ozdemir, N., Pabinger, I., Parra, R., Pasi, J., Peerlinck, K., Rauch, A., Roussel‐Robert, V., Serban, M., Tagliaferri, A., Windyga, J., Zanon, E.

“…Background Development of inhibitors is the most serious complication in haemophilia A treatment. The assessment of risk for inhibitor formation in new or…”
Get full text

P1525: MANAGEMENT OF AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING PREGNANCY OR POST‐PARTUM: AN INTERNATIONAL MULTI‐CENTRE EXPERIENCE by Bortolotti, M., Fantini, N. N., Glenthoj, A., Michel, M., Napolitano, M., Raso, S., Chen, F., McDonald, V., Murakhovskaya, I., Vos, J. M. I., Patriarca, A., Mingot‐Castellano, M. E., Prati, D., Barcellini, W., Fattizzo, B.

Get full text

P1647: CONTRIBUTION OF NEXT GENERATION FLOW (NGF) CYTOMETRY IN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP): UTILITY FOR THE DIFFERENTIAL DIAGNOSIS WITH MYELODYSPLASTIC SYNDROMES by Gonzalez‐Lopez, T. J., Matarraz, S., Caparros, I., Lopez‐Fernandez, M. F., Mingot‐Castellano, M. E., Jimenez Martin, A., Fernandez‐Fuertes, F., Sánchez Gallego, J. I., Leoz, P., Cuevas Ruiz, B., Cuevas Ruiz, M. V., Martin Marín, C., Olazabal Herrero, J., Vicente Cámara, P., Orfao, A.

Get full text

Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products by Megías-Vericat, J.E., Bonanad Boix, S., Berrueco Moreno, R., Mingot-Castellano, M.E., Rodríguez López, M., Canaro Hirnyk, M., Mateo Arranz, J., Calvo Villas, J.M., Haya Guaita, S., Mesegué Medà, M., López Jaime, F., Albo-López, C., Palomero-Massanet, A., Vilalta Seto, N., Leciñena, I. Larrodé, Haro, A.R. Cid, Poveda Andrés, J.L.

“…Extended half-life (EHL) factor VIII (FVIII) products have been designed to allow less frequent infusions and higher bleeding protection than standard…”
Get full text

Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT) by Gómez‐Seguí, I., Francés Aracil, E., Mingot‐Castellano, M. E., Vara Pampliega, M., Goterris Viciedo, R., García Candel, F., Pascual Izquierdo, C., Río Garma, J., Guerra Domínguez, L., Vicuña Andrés, I., Garcia‐Arroba Peinado, J., Zalba Marcos, S., Vidan Estévez, J. M., González Arias, E., Campuzano Saavedra, V., García Gala, J. M., Ortega Sanchez, S., Martínez Nieto, J., Pardo Gambarte, L., Solé Rodríguez, M., Fernández‐Docampo, M., Avila Idrovo, L. F., Hernández, L., Cid, J., Rubia Comos, J.

“…Summary Immune thrombotic thrombocytopenic purpura (iTTP) is an ultra‐rare disease that seldom occurs in the elderly. Few reports have studied the clinical…”
Get full text

PB2307: A MULTICENTER, RANDOMIZED, OPEN‐LABEL STUDY OF ROMIPLOSTIM PLUS DEXAMETHASONE VS DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA by Mingot Castellano, M. E., Bradbury, C. A., Rosso Fernández, C., Thomas, I., Alvarez‐Román, M. T., Canaro, M., Caparrós Miranda, I. S., Cappechi, M., Carpenedo, M., Evans, G., González‐Lopéz, J. T., González‐Porras, J. R., Jarque Ramos, I., Lozano‐Almela, M. L., Lopez Fernandez, M. F., Lowe, G., Lyall, H., Pascual Izquierdo, C., Pavord, S., Rayment, R., Roberts, P., Rosique Cortina, P., Sánchez‐González, B., Santoro, C., Talks, K., Valcarcel‐Ferreiras, D., Zaja, F.

Get full text

4CPS-252 Oral and intravenous iron in the treatment of perioperative anaemia by Fernández González, M, Alonso Moreno, M, Rodríguez Ramallo, H, Pérez Blanco, JL, Ciudad Gutierrez, P, Mingot Castellano, ME, Rubio Romero, R

“…Background and importanceAnaemia is common in the perioperative period and is associated with worse patient outcomes. Carboxymaltose intravenous iron (CII)…”
Get full text

4CPS-226 Effectiveness of carboxymaltose iron in preoperative anaemia treatment by Alonso Moreno, M, Rodriguez Ramallo, H, Perez Blanco, JL, Perez Maroto, MT, Mingot Castellano, ME, Rubio Romero, R

“…Background and importanceThe administration of carboxymaltose intravenous iron (CII) contributes significantly to the correction of perioperative anaemia and…”
Get full text

Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic‐guided prophylaxis based on Bayesian models with my PKF iT by Mingot‐Castellano, M. E., Parra, R., Núñez, R., Martorell, M.

Get full text

International recommendations on the diagnosis and treatment of patients with acquired hemophilia A by Huth-Kuhne, Angela, Baudo, Francesco, Collins, Peter, Ingerslev, Jorgen, Kessler, Craig M, Levesque, Herve, Castellano, Maria Eva Mingot, Shima, Midori, St-Louis, Jean

“…1 SRH Kurpfalzkrankenhaus Heidelberg gGmbH and Hemophilia Center, Heidelberg, Germany 2 Thrombosis and Hemostasis Unit, Niguarda Hospital, Milan, Italy 3…”
Get full text

Romiplostim: an advance in the treatment of idiopathic thrombocytopenic purpura by Mingot Castellano, M E

“…Primary Immune thrombocytopenia or idiopathic thrombocytopenic purpura (ITP) is an acquired immune disorder presenting with abnormal hemorrhagic symptoms…”
Get full text

Role of temperature and moisture, on monomer content of freeze-dried human albumin by Moreira, T, Cabrera, L, Gutierrez, A, Cádiz, A, Castellano, M E

Get more information

Acquired Haemophilia A: A Review of What We Know by Mingot-Castellano, Maria Eva, Rodriguez-Martorell, Francisco Javier, Nunez-Vazquez, Ramiro Jose, Marco, Pascual

“…Autoantibodies against plasma coagulation factors could be developed by some individuals inducing severe and sometimes fatal bleedings. This clinical entity is…”
Get full text

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study by Garcia-Donas, Jesus, MD, Esteban, Emilio, MD, Leandro-García, Luis Javier, BSc, Castellano, Daniel E, MD, del Alba, Aranzazu González, MD, Climent, Miguel Angel, MD, Arranz, José Angel, MD, Gallardo, Enrique, MD, Puente, Javier, MD, Bellmunt, Joaquim, MD, Mellado, Begoña, MD, Martínez, Esther, MD, Moreno, Fernando, MD, Font, Albert, MD, Robledo, Mercedes, PhD, Rodríguez-Antona, Cristina, Dr

“…Summary Background Sunitinib is a tyrosine kinase inhibitor with proven efficacy in renal-cell carcinoma, but some patients do not respond or need dose…”
Get full text